Cognitive improvement program using a serious game for multiple sclerosis patients

e-SEP Cognition: Effectiveness of a Remediation Program Via a "Serious Game" on the Cognitive Functions of Multiple Sclerosis Patients: Controlled, Randomized, Multicentric Trial

Not applicable Interventional Lille Catholic University · NCT04694534

This study tests a fun game designed to help people with multiple sclerosis improve their thinking skills and memory while they continue their regular treatment.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment150 (estimated)
Ages18 Years to 65 Years
SexAll
SponsorLille Catholic University Academic / other
Locations6 sites (Arras, Hauts-de-France and 5 other locations)
Trial IDNCT04694534 on ClinicalTrials.gov

What this trial studies

This study evaluates the effectiveness of a cognitive remediation program that utilizes a serious game to enhance information processing speed and episodic memory learning in patients with multiple sclerosis. Cognitive impairments are common in these patients, affecting their daily lives and quality of life. The program aims to provide a novel approach to address these cognitive deficits, which are often overlooked in traditional treatment plans. Participants will engage in the serious game alongside their usual care to assess improvements in cognitive function.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 65 with relapsing-remitting or progressive multiple sclerosis who exhibit cognitive complaints.

Not a fit: Patients with severe cognitive deficits or those unable to engage with the software due to motor or sensory difficulties may not benefit from this study.

Why it matters

Potential benefit: If successful, this program could significantly enhance cognitive functions and improve the quality of life for multiple sclerosis patients.

How similar studies have performed: While cognitive remediation strategies for multiple sclerosis are less studied, some existing research indicates that serious games may offer promising results in improving cognitive functions.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Relapsing-remitting or progressive multiple sclerosis people defined according to Mc Donald's criteria revised in 2005
* Age between ≥ 18 and ≤ 65 years old
* Cognitive complaint, with at least one deficient score at the initial neuropsychological examination (\<5th percentile of the reference group), one of the scores of which concerns at least one BICAMS test
* Have not had a definite relapse for at least 6 weeks
* Be at least 4 weeks away from a corticosteroid bolus
* Lack of neuroleptic treatment
* Patient with an Internet connection
* Signed informed consent

Exclusion Criteria:

* Severe cognitive deficit defined by obtaining a deficit score in more than six cognitive processes at the initial neuropsychological assessment.
* Neuropsychological care
* Inability to receive oral and written information
* Inability to use the software (due in particular to motor and / or sensory difficulties),
* Neurological or psychiatric comorbidity, other than MS and anxiodepressive syndrome
* Patient with severe anxiodepressive syndrome (BDI\> 27)
* Participation in an interventional study on cognitive functions
* Patient under legal protection, guardianship or curatorship
* Pregnant or breastfeeding women

Where this trial is running

Arras, Hauts-de-France and 5 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Multiple SclerosisMemoryLearningMultiple sclerosisSerious gameEpisodic memory learning capacitiesInformation processing speed capacities
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.